Roze bril schreef op 18 februari 2021 14:01:
Persbericht opgepikt uit Bolero. Vooral kijken naar de update over Barhemsys,
Feb 18 (Reuters) - ACACIA PHARMA GROUP PLC :
* PROPOSED CAPITAL RAISING BY WAY OF A PLACING OF NEW
ORDINARY
SHARES AND UPDATE ON EARLY POSITIVE MARKET RECEPTION TO US
LAUNCH OF BARHEMSYS®
* ANNOUNCES THAT IT INTENDS TO RAISE EUR 20 MILLION IN NEW
ORDINARY SHARES ( "NEW ORDINARY SHARES"), BY MEANS OF AN
ACCELERATED BOOKBUILD OFFERING ( "PLACING"), WITH POSSIBILITY TO
INCREASE SIZE OF PLACING.
* COMPANY ALSO PROVIDES A BRIEF UPDATE ON EARLY POSITIVE
MARKET
RECEPTION TO US LAUNCH OF BAHREMSYS(®)
* TO DATE, APPROXIMATELY 90% OF HOSPITALS THAT HAVE REVIEWED
BARHEMSYS(®) FOR ADDITION TO THEIR FORMULARY HAVE PLACED DRUG ON
FORMULARY RESULTING IN 90 ACCOUNTS ACROSS US WHERE PRODUCT IS
CURRENTLY AVAILABLE ON FORMULARY.
* BOOKBUILD WILL START IMMEDIATELY FOLLOWING THIS
ANNOUNCEMENT.
PRICING AND ALLOCATION OF NEW ORDINARY SHARES IN PLACING IS
EXPECTED TO TAKE PLACE BEFORE BEGINNING OF TRADING ON EURONEXT
BRUSSELS AT 09:00 CET ON 19 FEBRUARY 2021
* COMPANY WILL ANNOUNCE RESULTS OF PLACING AFTER CLOSING OF
BOOKBUILD IN A SUBSEQUENT ANNOUNCEMENT.